Toll Free: 1-888-928-9744

RedHill Biopharma Ltd. - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

RedHill Biopharma Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'RedHill Biopharma Ltd. - Product Pipeline Review - 2014', provides an overview of the RedHill Biopharma Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RedHill Biopharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of RedHill Biopharma Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of RedHill Biopharma Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the RedHill Biopharma Ltd.'s pipeline products

Reasons to buy

- Evaluate RedHill Biopharma Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of RedHill Biopharma Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the RedHill Biopharma Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of RedHill Biopharma Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of RedHill Biopharma Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of RedHill Biopharma Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
RedHill Biopharma Ltd. Snapshot 5
RedHill Biopharma Ltd. Overview 5
Key Information 5
Key Facts 5
RedHill Biopharma Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
RedHill Biopharma Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
RedHill Biopharma Ltd. - Pipeline Products Glance 15
RedHill Biopharma Ltd. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
RedHill Biopharma Ltd. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
RedHill Biopharma Ltd. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
RedHill Biopharma Ltd. - Drug Profiles 18
(rifabutin + amoxicillin sodium + omeprazole) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
(rifabutin + clarithromycin + clofazimine) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
carvedilol CR 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ondansetron hydrochloride CR 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RedHill Biopharma Ltd. - Pipeline Analysis 25
RedHill Biopharma Ltd. - Pipeline Products by Target 25
RedHill Biopharma Ltd. - Pipeline Products by Route of Administration 27
RedHill Biopharma Ltd. - Pipeline Products by Molecule Type 28
RedHill Biopharma Ltd. - Pipeline Products by Mechanism of Action 29
RedHill Biopharma Ltd. - Recent Pipeline Updates 31
RedHill Biopharma Ltd. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41
List of Tables
RedHill Biopharma Ltd., Key Information 5
RedHill Biopharma Ltd., Key Facts 5
RedHill Biopharma Ltd. - Pipeline by Indication, 2014 7
RedHill Biopharma Ltd. - Pipeline by Stage of Development, 2014 8
RedHill Biopharma Ltd. - Monotherapy Products in Pipeline, 2014 9
RedHill Biopharma Ltd. - Combination Treatment Modalities in Pipeline, 2014 10
RedHill Biopharma Ltd. - Partnered Products in Pipeline, 2014 11
RedHill Biopharma Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12
RedHill Biopharma Ltd. - Out-Licensed Products in Pipeline, 2014 13
RedHill Biopharma Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
RedHill Biopharma Ltd. - Phase III, 2014 15
RedHill Biopharma Ltd. - Phase II, 2014 16
RedHill Biopharma Ltd. - Preclinical, 2014 17
RedHill Biopharma Ltd. - Pipeline by Target, 2014 26
RedHill Biopharma Ltd. - Pipeline by Route of Administration, 2014 27
RedHill Biopharma Ltd. - Pipeline by Molecule Type, 2014 28
RedHill Biopharma Ltd. - Pipeline Products by Mechanism of Action, 2014 30
RedHill Biopharma Ltd. - Recent Pipeline Updates, 2014 31 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify